🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseGLP-1 hepatoprotection — my results so far Page 2

GLP-1 hepatoprotection — my results so far

lori_vegas Tue, Jan 9, 2024 at 3:54 PM 14 replies 2,207 viewsPage 2 of 3
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Jan 9, 2024 at 6:02 PM#6
pete_manc_UK said:
Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 312 dB/m (moderate steatosis) and stiffness 8.8 kPa (possible…

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
29 24SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 26 others
Reply Quote Save Share Report
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Jan 9, 2024 at 6:51 PM#7
lori_vegas said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase 3 ATTAIN trial. NASH resolution was achieved in ~60% of patients[1].

This is relevant to liver and MASH because survodutide's glucagon agonism specifically targets hepatic lipid metabolism — making it potentially the best-in-class agent for NASH/MAFLD comorbid with obesity.

References:
[1] Sanyal AJ, et al. N Engl J Med. 2024.
Last edited: Jan 9, 2024 at 11:51 PM
28 23Dr.PathRoch, mona_PHX, andrew_nyc and 25 others
Reply Quote Save Share Report
claudia_zurich
Member
389
1,678
Jul 2024
Zurich, CH
Jan 9, 2024 at 7:40 PM#8
Dr.MetabolicMD said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Coming at Dr.MetabolicMD’s question from a different direction. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.

27 22Dr.LipidDallas, alex_tucson, kevin_tulsa and 24 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
JakeBK_lifts
Member
523
2,345
Jul 2024
Brooklyn, NY
Jan 9, 2024 at 8:29 PM#9

Following on from DataDave — and this may be the naive question:

What did you change at the same time, and can you separate the two now?

26 21kate.chem, DataDave, Dr.GutHealth and 23 others
Reply Quote Save Share Report
lori_vegas
Member
378
1,678
Aug 2024
Las Vegas, NV
Jan 10, 2024 at 12:26 AM#10

OP back with an update, since a thread like this is useless without one.

Update: the thing I was blaming turned out not to be the cause. Leaving the original post as written rather than editing it, so the mistake stays visible for whoever searches this next.

Last edited: Jan 10, 2024 at 2:26 AM
20 18Dr.PathRoch, mona_PHX, andrew_nyc and 17 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register